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ABSTRACT
Background
Background and objective. We investigated immune recovery in 50 patients given either unma-
nipulated or CD8-depleted allogeneic peripheral blood stem cells after non-myeloablative con-
ditioning.
Design and Methods
Fifty patients were randomized to receive either CD8-depleted (n=22) or non-manipulated
(n=28) peripheral blood stem cells. The median patients age was 57 (range 36-69) years. The
conditioning regimen consisted of 2 Gy total body irradiation with or without added fludarabine.
Twenty patients received grafts from related donors, 14 from 10/10 HLA-allele matched unre-
lated donors, and 16 from HLA-mismatched unrelated donors. Graft-versus-host disease pro-
phylaxis consisted of mycophenolate mofetil and cyclosporine. Immune recovery during the first
year after hematopoietic cell transplantation was assessed by flow cytometry phenotyping,
analyses of the diversity of the TCRBV repertoire, and quantification of signal-joint T-cell recep-
tor excision circles (sjTREC).
Results
CD8-depletion of the graft reduced the recovery of CD8+ T-cell counts in the first 6 months fol-
lowing transplantation (p<0.0001) but had no significant impact on the restoration of other T-
cell subsets. Both sjTREC concentration and CD3+ T-cell counts increased significantly between
day 100 and 365 (p=0.010 and p=0.0488, respectively) demonstrating neo-production of T
cells by the thymus. Factors associated with high sjTREC concentration 1 year after transplan-
tation included an HLA-matched unrelated donor (p=0.029), a high content of T cells in the
graft (p=0.002), and the absence of chronic graft-versus-host disease (p<0.0001).
Conclusions
Our data suggest that while immune recovery is mainly driven by peripheral expansion of the
graft-contained mature T cells during the first months after non-myeloablative transplantation,
T-cell neo-generation by the thymus plays an important role in long term immune reconstitution
in transplanted patients.
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immunity, thymus.
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Introduction
Allogeneic hematopoietic cell transplantation (HCT) fol-
lowing non-myeloablative or reduced-intensity condition-
ing is being increasingly used in patients with hematologic
malignancies who are too old or too sick to tolerate a mye-
loablative allogeneic HCT,1 and in those who have failed an
autologous or allogeneic HCT following a myeloablative
regimen.2 These regimens are nearly exclusively dedicated
to the treatment of tumors through immune-mediated
graft-versus-tumor effects.3 Graft-versus-host disease
(GVHD) and infections are the most common complica-
tions leading to non-relapse mortality,4,5 underlying the
interest of analyzing immune reconstitution following
low-intensity conditioning.6-16
T-cell recovery after myeloablative allogeneic HCT
depends on both peripheral expansion of mature T cells
contained in the graft (thymus-independent pathway), and
T-cell neo-generation from donor hematopoietic stem cells
(thymus-dependent pathway).17-19 However, adequate
broadening of the T-cell repertoire is ensured primarily by
the latter.20 Following myeloablative allogeneic HCT, T-cell
neo-generation is considered as minimal in the early
months post-HCT, most circulating T cells being the prog-
eny of T cells infused with the graft during the first 6
months following HCT.21 In contrast, thymic production is
thought to play an important role in immune reconstitution
beyond day 100 in younger patients able to tolerate mye-
loablative conditioning, as demonstrated by the quantifica-
tion of signal joint T-cell receptor excision circles
(sjTREC).20,22-25 However, following myeloablative HCT,
naive T-cell counts remain low for prolonged periods, as a
consequence of the reduced survival capacity of these
cells.26
Previous studies analyzing immune recovery in (younger)
myeloablative recipients compared with (older) non-mye-
loablative recipients have suggested that, early after HCT,
patients undergoing non-myeloablative conditioning had
higher naive T-cell counts than those given  a myeloablative
regimen.9 This was attributed to the persistence of host-
derived naive T cells after non-myeloablative condition-
ing.9,27 However, 1 year after HCT, naive T-cell counts were
lower in non-myeloablative than in myeloablative recipi-
ents, suggesting that neo-generation of T cells might be low
in older recipients given non-myeloablative conditioning.9
This could be due to age-related thymic atrophy.28 Indeed,
after autologous HCT a significant thymic rebound has
been demonstrated in approximately 80% of patients
younger than 40 years old, in 50% of those 40 to 50 years
old, but in less than 15% of patients ≥50 years old.29 These
observations raise the question of whether successful
immune recovery through the thymic pathway can occur
in older patients given non-myeloablative conditioning, or
whether immune recovery in these patients can only occur
through peripheral expansion of transplanted T cells. 
CD8-depletion of the graft or of a donor lymphocyte
infusion has been proposed as a way to decrease the inci-
dence of GVHD without affecting graft-versus-tumor
effects.30-35 We recently performed a comparative study of
the impact of CD8-depletion of peripheral blood stem cells
(PBSC) on clinical outcomes in a group of 50 patients ran-
domly assigned to receive unmanipulated or CD8-depleted
PBSC following non-myeloablative conditioning.36 The
results of this study are summarized in Table 1. Briefly,
CD8-depletion of PBSC failed to reduce the incidence of
grade II-IV acute GVHD, but was associated with an
increased risk of graft rejection. Relapse/progression rate
and overall survival were similar in the two arms of the
study.36
Here we analyze, on the same groups of patients given
allogeneic PBSC after non-myeloablative conditioning, the
importance of both peripheral T-cell expansion and thymic
production on immune recovery.
Design and Methods
T-cell receptor excision circles assay
sjTRECs were quantified in each sample by nested real-
time polymerase chain reaction (PCR), as previously
described.26;43;44 Briefly, thawed peripheral blood mononu-
clear cells (PBMC) were lysed for 30 min at 56°C with
Table 1. Patients.
Unmanipulated CD8-depleted p-value
PBSC (n=28) PBSC (n=22)
Recipient age median (range), years 57 (41-65) 57 (36-69) NS
Donor age median (range), years 40 (18-70) 45 (27-67) NS
Donor type, no.
HLA-identical sibling 11 8 NS
One antigen mismatched related donor 1 0 NS
10/10 HLA-allele matched unrelated donor 8 6 NS
HLA-mismatched unrelated donor 8 8 NS
Diagnoses, no. of patients 
Acute myeloid leukemia 3 0
Myelodysplastic syndrome/   
myeloproliferative disorder 7 9
Chronic myeloid leukemia 0 2
Lymphoma 8 6
Chronic lymphocytic leukemia 1 4
Multiple myeloma 7 1
Renal cell carcinoma 2 0
Conditioning regimen, no. of patients
2 Gy TBI 7 5
2 Gy TBI + fludarabine (90 mg/m2) 21 17
Median (range) no. of cells infused (x 106/kg)
CD34+ cells 4.2 (0.8-20.2)3.7 (0.7-12.2) 0.21
CD3+ T cells 319 (80-631) 110 (56-239) <0.0001
CD4+ T cells 180 (38-406) 94 (57-220) 0.0003
CD8+ T cells 130 (43-272) 4.2 (0.4-33.7) <0.0001
Acute GVHD, no. of patients 
Grade II 7 7 NS
Grade III 1 1 NS
rade IV 4 0 0.06
Chronic GVHD, no. of patients 9 4 NS
Graft rejection, no. of patients 0 7 0.001
2-year overall survival (%) 59 53 NS
TBI, total body irradiation; GVHD, graft-versus-host disease
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Tween-20 (0.05%), NP-40 (0.05%) and proteinase K (100
µg/mL). Cell lysis was stopped by incubation for 15 min at
99°C. Multiplex PCR amplification was achieved for
sjTREC together with the CD3γ chain, used as a house-
keeping gene, with specific 3’/5’ outer primers for each
amplicon. Cycle conditions and primers/probes sequences
have been reported elsewhere.26,43 PCR products were dilut-
ed 10-fold prior to PCR quantification using Lightcycler™
technology.  The quantitative PCR conditions were: 1 min
initial denaturation at 95°C followed by 40 cycles of ampli-
fication (1 second at 95°C, 10 seconds at 60°C, 15 seconds
at 72°C). Fluorescence emissions were assessed after the
hybridization steps. Each PCR product was run for both
sjTREC and CD3γ chains in two separate Lightcycler
experiments. Every sample was run in triplicate, in three
different experiments. The results were first calculated as
absolute number of sjTREC per 105 PBMC; because each
PBMC contains two CD3γ chain copies, sjTREC/105 PBMC
= (sjTREC/CD3γ) x 2×105. Because sjTREC are only present
in lymphocytes, and because the composition of PBMC is
variable, the concentration of sjTREC in peripheral blood
was computed using the formula: [(sjTREC / 105 PBMC ×
PBMC/µL) /100 where PBMC/µL = (white blood cells /µL
× (%lymphocytes + %monocytes)]/100. Similar adjust-
ments for calculating absolute T-cell subset counts from
their frequencies in PBMC have been made previously by
other groups of investigators.45 The nested character of this
quantitative PCR is endowed with a high sensitivity (detec-
tion of one copy of sjTREC per PCR reaction).
Statistical analyses
The two-way analysis of variance (ANOVA) test with
graft manipulation and time as variables was used to com-
pare T-cell subset recovery and evolution of T-cell
chimerism in recipients of unmanipulated graft and those
receiving CD8-depleted PBSC. Logarithmic transforma-
tion of the data was used before ANOVA analyses. The
Mann-Whitney test was used to compare graft composi-
tion, TCRBV repertoire diversity and sjTREC levels in
recipients of unmanipulated grafts and those receiving
CD8-depleted PBSC. Wilcoxon’s matched pair test was
used to compare TCRBV repertoire diversity, sjTREC con-
centration and CD3+ T-cell counts at day 40 or 100 after
HCT with values obtained in the same patients on day
365 after HCT. Spearman’s correlation test was used to
analyze potential associations between graft composition
and counts of T-cell subsets and sjTREC levels after HCT,
as well as between donor’s and patient’s age and sjTREC
levels after HCT. The probabilities of disease progression
and severe infection (defined as sepsis, cytomegalovirus
disease or invasive fungal infection) from day 100 to day
365 according to immune recovery on day 100 after HCT
was assessed using the Kaplan-Meier method. Statistical
analyses were carried out with Graphpad Prism
(Graphpad Software, San Diego, CA, USA).
To determine factors affecting the counts of CD3+ T
cells, naive CD4+ T cells, and CD8+ T cells on days 100,
180 and 365 after HCT, as well as sjTREC concentration
on days 100 and 365 after HCT, multivariate linear
regression models for the different T-cell subset counts
and sjTREC concentrations at each time point were fitted
with the SAS Reg procedure (SAS Institute, Cary, NC,
USA) using forward stepwise selection. Selected models
were refitted for all patients since some patients were
excluded in the stepwise selection because of missing
values for variables not retained in the final model.
Potential factors examined were donor type (HLA-identi-
cal sibling vs. 10/10 HLA-allele-matched unrelated donor
vs. HLA-mismatched unrelated donor), recipient age,
donor age, graft content of CD3+ T cells (CD8+ T cells for
CD8+ T-cell counts, and CD34+ cells for sjTREC concen-
tration), acute GVHD and chronic GVHD. Logarithmic
transformation of the responses was used for all models.
The threshold level of statistical significance was 0.05.
Results
T-cell chimerism
Median donor CD3+ T-cell chimerism levels in unma-
nipulated and CD8-depleted recipients were, respective-
ly, 71 and 51% (p=0.1), 73 and 65% (p=0.5), 75 and 70%
(p=0.23), 75 and 70% (p=0.3), and 89 and 81% (p=0.4) on
days 28, 42, 100, 180 and 365. When analyzed together
with the two-way ANOVA test, recipients of unmanipu-
lated PBSC had higher levels of donor T-cell chimerism
than had recipients of CD8-depleted PBSC (p=0.01)
(Online supplementary Figure 1A).
Reconstitution of peripheral lymphocyte subsets 
Peripheral lymphocyte subset reconstitution was ana-
lyzed in both groups of patients (Online supplementary
Figure 1). Following transplantation, paralleling the increase
in CD3+ T cells of donor origin (Online supplementary Figure
1B), CD4+, CD8+, naive CD4+ (CD4+CD45RA+) and memo-
ry CD4+ (CD4+CD45RO+) T cells were almost completely
reconstituted over the first year of follow-up (Online sup-
plementary Figure 1C to G). 
CD8-depletion of PBSC did not significantly affect CD3+,
CD4+, CD4+CD45RA+, and CD4+CD45RO+ lymphocyte
recovery. In contrast, it significantly reduced the reconstitu-
tion efficiency of the CD8+ compartment (p<0.0001) as
well as that of the CD56+ lymphocyte population (p=0.01).
Furthermore, the expansion of CD3+ T lymphocytes of
donor origin was slowed down following CD8-depletion
of PBSC (p=0.06). Interestingly, we observed a correlation
between the number of CD3+ T cells present in the graft
and CD3+ T-cell counts on days 28 (Spearman’s R=0.39,
p=0.02) and 100 (Spearman’s R=0.39, p=0.04) after HCT,
but neither at 180 nor at 365 days after HCT. 
T-cell repertoire reconstitution
In order to evaluate T-cell repertoire diversity in trans-
planted patients, we performed a spectratype analysis in
E. Castermans et al.
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both groups of patients at 40, 100, 180 days and 1 year
post-transplant. The overall T-cell repertoire complexity
was evaluated by scoring the number of peaks identified in
the 24 TCRBV families as described previously42 and com-
paring the results from five volunteer donors. At 40 days
post-transplantation, TCRBV diversity was slightly
reduced in both unmanipulated and CD8-depleted PBSC
recipients, as compared to healthy control individuals
(mean±SD TCRBV scores were 186±5 peaks in controls,
versus 166±31 peaks in the patients (p=0.09)). Moreover,
despite a subsequent increase in circulating T-cell numbers
during the first year post-transplantation, TCR diversity
continued to decrease in both groups of patients (mean ±
SD TCRBV scores in all patients: 158±40 peaks (p=0.04 in
comparison to the volunteer donors) and 151±40 peaks
(p=0.02 in comparison to the volunteer donors) on days
100 and 365, respectively) (Figure 1A). Despite marked dif-
ferences in the number of transplanted CD8+ T cells,
TCRBV diversity was similar in unmanipulated PBSC and
CD8-depleted PBSC recipients at all time points (p=0.68,
p=0.93, and p=0.34 at 40, 100 and 365 days post-transplant,
respectively). Furthermore, at day 180 after HCT, TCRBV
scores in both CD8+ (134±56 vs. 112±73 peaks, p=0.4) and
CD4+ (152±65 vs. 157±35 peaks, p=0.8) T cells did not dif-
fer significantly between unmanipulated and CD8-deplet-
ed PBSC recipients. Finally, as shown in Figure 1B-C, graft
manipulation, patient-donor relationship and occurrence of
chronic GVHD did not significantly affect TCRBV scores. 
The observation of a time-dependent reduction of the
TCRBV diversity suggests that while the initial reconstitu-
tion phase is principally dependent on peripheral expan-
sion of transplanted mature T cells, these cells are then
depleted over the first year, leading to a reduced T-cell
receptor repertoire. However, this reduction of peripheral
T-cell repertoire is accompanied by an increased number of
circulating T cells, suggesting another source of these cells. 
Thymic function 
In order to analyze the contribution of de novo T-cell pro-
duction by the thymus to the overall T-cell reconstitution,
we quantified sjTREC frequencies (sjTREC/105 cells) and
sjTREC concentrations (sjTREC/mL) in the two groups of
patients on days 100 and 365 after HCT (Online supplemen-
tary Figure 2). At day 100 post-HCT, sjTREC frequencies
and concentrations were significantly higher in patients
receiving unmanipulated PBSC than in those who received
CD8-depleted cells (median sjTREC frequency = 67 [1-580]
and 10 [1-120] sjTREC/105 cells in the unmanipulated and
CD8-depleted groups, respectively (p=0.003); median
sjTREC concentration = 391 [9-5614] and 149 [5-1495]
sjTREC/mL, respectively (p=0.008, Online supplementary
Figure 2A). In contrast, the two groups had similar sjTREC
frequencies and concentrations at 1 year post-transplant
(median sjTREC frequency = 107 [3-492] and 47 [1-167]
sjTREC/105 cells; median sjTREC concentrations = 697 [25-
2136] and 1022 [129-22927] sjTREC/mL in the untreated
and CD8-depleted groups respectively). Whether or not
these levels of thymic output are sufficient to provide suc-
cessful long-term immune recovery with broad diverse T-
cell repertoires several years after HCT is the focus of
ongoing studies.  
Interestingly, the sjTREC concentration was inversely
correlated with age in both groups of patients at 1 year
post-transplant (r=-0.64, p=0.0187 and r=-0.57; p=0.2 for
Figure 1. (A) TCRBV repertoire in five volunteer healthy blood
donors, and in patients on days 40, 100 and 365 after HCT. (B)
TCRBV repertoire on day 100 after HCT in patients given unma-
nipulated or CD8-depleted (CD8-) PBSC, as well as in patients
receiving grafts from HLA-matched related (MRD), HLA-identical
unrelated (HLA-id-URD), or HLA-mismatched unrelated (MM-URD)
donors. (C) TCRBV repertoire on day 365 after HCT in patients
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the recipients of unmanipulated grafts and CD8-depleted
grafts, respectively (Online supplementary Figure 2C); r=-
0.57 and p=0.008 when all patients were analyzed togeth-
er). Such a correlation, which did not exist at 100 days,
suggests that de novo T-cell production by the thymus is an
important parameter for the production of recent thymic
emigrants (RTE) in transplanted patients at 1 year post-
transplantation. In order to assess directly whether neo-
generation of T cells through the thymic pathway
occurred between days 100 and 365 after HCT, we com-
pared sjTREC concentrations and CD3+ T-cell counts on
days 100 and 365 after HCT in a group of 16 patients for
whom we had sjTREC data on both day 100 and day 365
after HCT. The median age of the patients in this cohort
was 54 (range, 36-64) years. Both sjTREC concentrations
and CD3+ T-cell counts increased significantly between
days 100 and 365 (p=0.010 and p=0.0488, respectively)
(Figure 2A). Moreover, there was a suggestion of a nega-
tive correlation between higher patient’s age and lower
sjTREC increment from day 100 to 365 (Spearman’s R=-
0.45, p=0.078). Furthermore, at both time points, the
sjTREC frequency strongly correlated with the sjTREC
concentration [r=0.93, p<0.001, and r=0.93, p=0.007,
respectively (Online supplementary Figure 2D)], demonstrat-
ing that peripheral proliferation does not have a major
impact on the number of circulating T cells, at least in the
compartment of recent thymic emigrants.
Multivariate analysis of factors affecting immunologic
recovery (Table 2)
Recipient age. High recipient age was associated with low
naive CD4+ T-cell counts on day 365 after HCT (p=0.02).
Donor age and type. High donor age was associated with
lower counts of both CD3+ T cells (p=0.02) and CD8+ T
cells (p=0.02) on day 365 after HCT. Having a HLA-
matched unrelated donor was associated with high sjTREC
concentrations on day 365 after HCT (p=0.03) (Figure 2B).
Graft composition. High numbers of transplanted CD3+ T
cells were associated with high CD3+ T-cell counts on day
100 after HCT (p=0.01). This association was not present
on day 180 or 365 after HCT. High numbers of transplant-
ed CD3+ T cells were also associated with high sjTREC
concentrations after HCT (p=0.002). High numbers of
transplanted CD8+ T cells were associated with high CD8+
T-cell counts on days 100 (p=0.001) and 180 (p=0.04) after
HCT. This association was not present on day 365 after
HCT. There was no association between numbers of trans-
planted CD34+ cells and sjTREC concentrations on day 100
or 365 after HCT.
GVHD. The occurrence of grade II-IV acute GVHD was
associated with lower counts of both CD3+ T cells (p=0.02)
and CD8+ T cells (p=0.049) after HCT. The occurrence of
chronic GVHD was associated with a low sjTREC concen-
tration on day 365 after HCT (p<0.001) (Figure 2C).
Associations between immune recovery and disease pro-
gression/infections
There was no significant association between the occur-
rence of severe infections (defined as sepsis, cyto-
megalovirus disease or invasive fungal disease) on days 100
and 365 after HCT in patients with sjTREC concentrations,
CD3+ cell counts or CD4+CD45RA+ cell counts below or
above the median. Similarly, there was no significant asso-
ciation between the incidence of disease progression on
days 100 and 365 after HCT in patients with sjTREC con-
centrations, CD3+ cell counts or CD4+CD45RA+ cell counts
below or above the median.




Figure 2. (A) Median sjTREC concentrations and CD3+ T-cell counts
on days 100 and 365 after HCT in a group of 16 patients for
whom we had sjTREC data on both day 100 and day 365 after
HCT. The median age of the patients in this cohort was 54 (range,
36-64) years. Error bars indicate interquartile ranges. (B) sjTREC
concentrations 1 year after HCT in patients given grafts from relat-
ed (MRD), HLA-identical unrelated (HLA-id-URD) or HLA-mis-
matched unrelated (MM-URD) donors. (C) sjTREC concentrations 1








































































haematologica | 2008; 93(2) | 245 |
Immunity after non-myeloablative HCT
Discussion
Whether or not successful immune recovery through
the thymic pathway can occur in older patients given
non-myeloablative conditioning has remained an impor-
tant unsolved question. In this study, we evaluated
immune recovery in patients receiving allogeneic PBSC
transplantation after non-myeloablative conditioning.
This study was part of a prospective randomized trial
aimed at assessing the impact of CD8-depletion of PBSC
on the risk of development of GVHD in patients who
cannot undergopre-transplant myeloablative treatment.
We show that the immune recovery period can be divid-
ed into two major phases. During the first 3 months post-
transplantation, most of the immune reconstitution is
principally a consequence of the expansion of the mature
T cells present in the graft. However, de novo production
by the thymus cannot be excluded during this period. In
contrast, following this early phase, the thymus seems to
be a major source of circulating T cells in the patients.
There was a strong correlation between graft composi-
tion and both CD3+ T-cell counts and CD8+ T-cell counts
in the first 100 days after HCT, suggesting that immune
recovery was mainly driven by peripheral expansion of
mature T cells present in the graft early after HCT. These
observations are in agreement with the results of previous
studies performed in younger patients undergoing mye-
loablative allogeneic HCT.46 Indeed, Hochberg et al. found
that TREC levels remained low in the first 3 months fol-
lowing myeloblative allogeneic bone marrow transplanta-
tion in adults.23 In addition, patients given T cell-depleted
grafts had lower levels of both naive T cells47 and sjTREC24
in the first months following myeloablative conditioning,
in comparison to those given unmanipulated grafts.
Furthermore, naive T-cell counts 100 days after myeloab-
lative HCT were strongly correlated with the number of
naive T cells in the graft.21 Similarly, after non-myeloabla-
tive conditioning, the number of TREC-positive cells was
shown to decrease gradually in the first 6 months follow-
ing HCT, suggesting that the main mechanism of T-cell
reconstitution early after non-myeloablative conditioning
is thymus-independent.10 Finally, another study suggested
that graft composition was the main factor affecting
immune recovery during the first 6 months following
non-myeloablative HCT.7
Importantly, our data demonstrated that neo-genera-
tion of T cells through the thymic pathway was a major
source of circulating T cells 1 year after HCT. The impor-
tant role of neo-generation of T cells by the thymus after
non-myeloablative conditioning was rather surprising,
given the fact that this strategy is mainly proposed for
older patients. Indeed, in the current study, 50% of the
patients were older than 57 years, and 25% older than 63.
While TREC concentrations 1 year after HCT were
inversely correlated with the patients’ age in univariate
analysis, absence of chronic GVHD, a high number of
CD3+ T cells in the graft and HLA-matched unrelated
donor were the three main factors affecting this concen-
tration. These findings are in agreement with previous
observations in younger patients given allogeneic grafts
following myeloablative conditioning, which showed
that graft composition,24 recipient age24,48 and absence of
chronic GVHD22,24,25 were the main factors affecting
thymic function the first year following HCT.24,48 While
the negative impact of chronic GVHD on thymic function
could be due to both direct destruction of host thymic
epithelium by chronic GVHD and the negative impact of
immunosuppressive drugs,49,50 the association between
high numbers of CD3+ T cells in the graft and high
sjTREC concentrations could be due to both a higher
sjTREC content in the graft and a lower need for periph-
eral T-cell expansion (and thus less dilution of sjTREC) in
patients whose grafts contained more T cells. The associ-
ation between high sjTREC levels and HLA-matched
unrelated donors could be due to both impaired thymic
function (maybe through subclinical alloreactivity of
donor T cells towards recipient thymic epithelium) in
patients given grafts from HLA-mismatched unrelated
donors,50 and older donors’ age (and thus lower frequen-
cy of prethymic T-cell progenitors) in patients given grafts
from HLA-identical siblings.14 Although we did not per-
form computed tomography scans of the thoracic inlet to
demonstrate newly emerging thymic shadows, previous
studies found a strong correlation between thymic size
increment and sjTREC levels after HCT,29 suggesting that
sjTREC-positive cells are mainly generated by the thymus
also in the HCT setting. 
Finally, our study showed that the T-cell repertoire
remained relatively diversified early after HCT, but was
more restricted 1 year after HCT. While the relatively
complex T-cell repertoire early after HCT could be partly
Table 2. Multivariate analyses of factors affecting immune recov-
ery after non-myeloablative conditioning*.
Cell subset Day Factor(s) associated with higher 
after HCT cell subset counts
CD3+ T cells 100 High no. of CD3+ T cells transplanted† (p=0.010)
Absence of grade II-IV acute GVHD (p=0.021)
365 Low donor age† (p=0.017)
Naive CD4+ T cells 365 Low recipient age† (p=0.021)
CD8+ T cells 100 High no. of CD8+ T cells transplanted† (p=0.001)
Absence of grade II-IV acute GVHD (p=0.049)
180 High no. of CD8+ T cells transplanted† (p=0.036)
365 Low donor age† (p=0.015)
sjTREC 365 10/10 HLA-allele-matched unrelated donor (p=0.029)
Absence of chronic GVHD (p<0.0001)
High no. of CD3+ T cells transplanted† (p=0.002)
*Potential factors examined were donor type (HLA-identical sibling vs. 10/10
HLA allele-identical unrelated donor vs. HLA-mismatched unrelated donor),
recipient age, donor age, graft content of CD3+ T cells (CD8+ T cells for CD8+
T-cell counts, and CD34+ cells for sjTREC concentration), acute GVHD and
chronic GVHD. †continuous linear variable; No., number; CMV,
cytomegalovirus; TBI, total body irradiation; CSP, cyclosporine; MMF,
mycophenolate mofetil; GVHD, graft-versus-host disease.
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due to the persistence of host-derived T cells,9,27 the more
restricted T-cell repertoire seen at 1 year could be the con-
sequence of gradual eradication of residual host-derived T
cells by donor-derived T cells,9,27 or death of mature T cells
contained in the graft following their massive expansion.
Alternatively, since analysis of the T-cell repertoire cannot
definitively distinguish between T-cell loss and T-cell
expansion, the more restricted T-cell repertoire observed
at 1 year could be due to massive clonal expansion of spe-
cific memory T-cell clones, such as cytomegalovirus-spe-
cific clones, or clones causing GVHD.51
In summary, our results suggest that while immune
recovery was mainly driven by peripheral expansion of
mature T cells contained in the graft during the first 3
months after non-myeloablative transplantation, T-cell
neo-generation by the thymus plays an important role in
long-term immune reconstitution in transplanted
patients.
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